YESU ADDEPALLI

Dr. YESU ADDEPALLI

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ROHAN KALYAN REJROHAN KALYAN REJ
ROHAN KALYAN REJ
SASrinivasa Rao Allu
Srinivasa Rao Allu
JRJoyeeta Roy
Joyeeta Roy
RARanjan Kumar Acharyya
Ranjan Kumar Acharyya
CNchaithanya kiran indukuru naga
chaithanya kiran indukuru naga
DVDhamodharan Venugopal
Dhamodharan Venugopal
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.

16 January 2018 in Organic Letters
Verified
Journal Article
Closed access
ZWZhen Wang
Zhen Wang
YAYESU ADDEPALLI
YESU ADDEPALLI
YHYun He
Yun He

11 September 2019 in Chemistry – An Asian Journal
Verified
Journal Article
Closed access
PDF file
XWXin Wang
Xin Wang
MLMengxue Lu
Mengxue Lu
QSQin Su
Qin Su
MZMinghui Zhou
Minghui Zhou
YAYESU ADDEPALLI
YESU ADDEPALLI
YLYixin Lu
Yixin Lu

23 March 2018 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MZMinghui Zhou
Minghui Zhou
QSQin Su
Qin Su
YAYESU ADDEPALLI
YESU ADDEPALLI
YHYun He
Yun He
ZWZhen Wang
Zhen Wang
An unprecedented Lewis acidic gold( i )-complex generated from chiral BINAP and PPh 3 AuCl has been developed for the Mannich reaction of α-diazocarbonyl compounds and N -sulfonyl cyclic ketimines.

20 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RTRachel Tesla
Rachel Tesla
CGCharlotte Guhl
Charlotte Guhl
GWGordon C. Werthmann
Gordon C. Werthmann
DDDanielle Dixon
Danielle Dixon
BCBasar Cenik
Basar Cenik
JHJoachim Herz
Joachim Herz
Heterozygous loss-of-function mutations in the GRN gene are a major cause of hereditary frontotemporal dementia. The mechanisms linking frontotemporal dementia pathogenesis to progranulin deficiency are not well understood, and there is currently no treatment. Our strategy to prevent the onset and progression of frontotemporal dementia in patients with GRN mutations is to utilize small molecule positive regulators of GRN expression to boost progranulin levels from the remaining functional GRN allele, thus restoring progranulin levels back to normal within the brain. This work describes a series of blood-brain-barrier-penetrant small molecules which significantly increase progranulin protein levels in human cellular models, correct progranulin protein deficiency in Grn+/− mouse brains, and reverse lysosomal proteome aberrations, a phenotypic hallmark of frontotemporal dementia, more efficiently than the previously described small molecule suberoylanilide hydroxamic acid. These molecules will allow further elucidation of the cellular functions of progranulin and its role in frontotemporal dementia and will also serve as lead structures for further drug development.

11 August 2021 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
ZXZongli Xiong
Zongli Xiong
JDJingxiang Duan
Jingxiang Duan
XLXiaoyi Li
Xiaoyi Li
XWXin Wang
Xin Wang
YAYESU ADDEPALLI
YESU ADDEPALLI
ZWZhen Wang
Zhen Wang